Findings showed a statistically significant and clinically meaningful improvement in the mADL11 score at week 8 with ulixacaltamide vs placebo. Topline data were announced from two phase 3 trials ...

A Prescription Drug User Fee Act target date of January 29, 2027 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ...

Shares of Praxis Precision Medicines hit their highest intraday level since March 2022 Biopharmaceutical company Praxis Precision Medicines says that Phase 3 trials of its ulixacaltamide drug have ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

A committee of outside clinical trial observers has recommended that Praxis Precision Medicines stop testing its experimental treatment for essential tremor after an interim analysis of one study ...

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. The Breakthrough Therapy Designation was granted ...

“Patients in Essential3 had been living with essential tremor for an average of 30 years, with worsening symptoms and no effective treatment options. In just 15 months of recruitment, we had over ...

Approximately 70% of Praxis Precision Medicines, Inc.'s modeled pipeline value depends on Ulixacaltamide’s approval for essential tremor, making the investment highly concentrated on this catalyst.

BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines (PRAX), Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of ...

Shares of biopharmaceutical company Praxis Precision Medicines Inc. soared Thursday, boosted by the successful trial of a new drug to treat movement disorders. The drug, ulixacaltamide, targets ...